The FTC on Monday filed an amicus brief in Mylan Pharmaceuticals’ antitrust lawsuit alleging that Sanofi abused the FDA’s Orange Book to delay and block Mylan’s generic insulin from competing with Sanofi.
In the suit, filed in May in the US District Court for the Western District of Pennsylvania, Mylan (now known as Viatris) alleges that Sanofi used the Orange Book process to block the biosimilar to insulin known as Semglee from competing with Sanofi’s branded product.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.